Innate Pharma Investor Relations Material
Latest events
Q2 2025
Innate Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Innate Pharma S.A.
Access all reports
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications. It generates its products from the expression platforms based on its phage display and dAb technologies. The company's lead product is NexoBrid, which is a treatment for severe burns that can be used outside of the European Union; and Phase 3 NExoBrid clinical trial is completed in Europe. Innate Pharma S.A. was founded in 2000 as Innate ImmunoPharmaceuticals S.A.; and it changed its name to Innate Pharma S.A. in 2011. Innate Pharma S.A. has operations in Saint Prex, Switzerland; and Sophia Antipolis, France. Innate Pharma S.A is based in Marseille, France.
Key slides for Innate Pharma S.A.
Corporate Presentation
Innate Pharma S.A.
Q2 2025
Innate Pharma S.A.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IPH
Country
🇫🇷 France